DHR vs GRFS vs CDXS Stock Comparison

Danaher, Grifols and Codexis Prices as of Nov 4, 2026 Peers: Industry group
1 more company in this comparison (RVTY) Create a free account to keep reading and compare up to 10 companies.
DHR Danaher Corp /De/
$234.94 +6.2% 1M +9.9% 1Y
Market cap
$164.30B
P/E
37.9x
Revenue (TTM)
$25.61B
Div. yield
–
Life Sciences Tools Healthcare
7 wins
GRFS Grifols SA
$8.60 +16.1% 1M -6.7% 1Y
Market cap
$5.82B
P/E
12.9x
Revenue (TTM)
—
Div. yield
–
Biotechnology Healthcare
2 wins
CDXS Codexis, Inc.
$1.08 -22.3% 1M -50.2% 1Y
Market cap
$97.44M
P/E
–
Revenue (TTM)
$77.68M
Div. yield
–
Life Sciences Tools Healthcare
2 wins

Head to Head

11 decided of 12

Danaher leads on 7 of the 12 questions below (Danaher 7, Grifols 2, Codexis 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionDHRGRFSCDXSLeader
Larger companyMarket capitalisation $164.30B $5.82B $97.44M DHR
Cheaper on earningsLower P/E, profitable companies only 37.9x 12.9x -3.2x GRFS
Cheaper on forward earningsLower price / next fiscal year consensus EPS 25.8x 9.1x — GRFS
Faster revenue growthRevenue growth, trailing twelve months +5.5% — +35.9% CDXS
More profitableNet margin, trailing twelve months 16.9% — -39.6% DHR
Better return on capitalReturn on invested capital 5.8% — -35.1% DHR
Less leveragedLower net debt / EBITDA 2.6x — 0.7x CDXS
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +9.9% -6.7% -50.2% DHR
Better 5-year returnAnnualised price return, 5 years -4.3%/yr -6.8%/yr -51.5%/yr DHR
Less volatileAnnualised volatility, 1 year 30.8% 32.6% 87.5% DHR
Higher overall scoreMean of the five percentile scores vs peers 61/100 56/100 45/100 DHR

Percentile Scorecard

DHRGRFSCDXS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisDHRGRFSCDXS
Valuation 71 #67 of 229 99 #9 of 634 43 #132 of 229
Growth 26 #164 of 221 – 67 #73 of 221
Profitability 86 #31 of 209 – 43 #120 of 209
Financial Health 48 #126 of 240 14 #566 of 654 30 #168 of 240
Shareholder Returns 72 #41 of 146 57 #173 of 400 43 #84 of 146
Overall 61 56 45
  • DHR ranked among 248 companies in Medical Devices and Diagnostics
  • GRFS ranked among 671 companies in Pharmaceuticals and Biotechnology
  • CDXS ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodDHRGRFSCDXSSPY
1 month +6.2%+16.1%-22.3% -1.0%
3 months +17.7%+8.4%-25.5% -0.4%
6 months +34.3%+2.3%-59.4% +4.5%
Year to date +2.6%-8.0%-33.7% +12.4%
1 year +9.9%-6.7%-50.2% +13.6%
3 years +18.7%-7.6%-44.0% +76.4%
3 years, per year +5.9%-2.6%-17.6% +20.8%
5 years -19.6%-29.6%-97.3% +63.7%
5 years, per year -4.3%-6.8%-51.5% +10.4%
10 years +205.4%-41.1%-76.5% +267.7%
10 years, per year +11.8%-5.2%-13.5% +13.9%

Risk

MeasureDHRGRFSCDXSSPY
Volatility, 1Y 30.8%32.6%87.5% 12.8%
Downside volatility, 1Y 32.0%34.1%92.9% 12.7%
Beta vs S&P 500, 1Y 0.500.881.85 1.00
Return / volatility, 1Y 0.32-0.21-0.57 1.06
Max drawdown, 5Y -50.8%-58.8%-97.7% -25.4%
From 52-week high -2.9%-11.5%-62.1% -1.6%
52-week high $242.05$9.72$2.85 $779.14
52-week low $161.91$7.02$0.98 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleDHRGRFSCDXS
P/E now vs peer median 38.2xmedian 28.5x 12.9xmedian 18.0x -3.2xmedian 28.5x
P/S now vs peer median 6.5xmedian 2.9x 0.7xmedian 9.1x 1.3xmedian 2.9x
EV/EBITDA now vs peer median 23.7xmedian 18.5x —median 16.2x -4.0xmedian 18.5x
P/FCF now vs peer median 28.9xmedian 26.7x 8.3xmedian 21.7x -8.1xmedian 26.7x
P/B now vs peer median 3.1xmedian 2.3x 0.7xmedian 2.2x 3.0xmedian 2.3x
PEG now vs peer median -4.76median 0.93 —median 0.38 -0.12median 0.93

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsDHRGRFSCDXS
Revenue $25.61B – $77.68M
Gross profit $15.01B – $67.60M
Operating income $5.22B – -$27.66M
Net income $4.33B – -$30.72M
Free cash flow $5.73B – -$12.18M
R&D $1.67B – $48.74M
EPS (diluted) $6.13 – $-0.34
Cash & equivalents $5.68B $969.15M $27.17M
Total debt $26.48B $11.33B $40.88M
Shares (diluted) 706.80M 681.57M 91.05M
Enterprise value $143.95B $2.16B -$159.61M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricDHRGRFSCDXS
P/E 38.2x 12.9x -3.2x
P/FCF 28.9x 8.3x -8.1x
P/Operating cash flow 24.1x – -9.5x
P/S 6.5x 0.7x 1.3x
P/B 3.1x 0.7x 3.0x
P/Tangible book 5.1x 1.0x 3.0x
EV/EBITDA 23.7x – -4.0x
EV/EBIT 35.7x – -3.1x
EV/Revenue 7.3x – 1.1x
EV/FCF 32.5x – -7.0x
EV/Operating cash flow 27.1x – -8.1x
PEG (3Y EPS CAGR) -4.76 – -0.12

Growth

14 metrics
MetricDHRGRFSCDXS
Revenue growth (1Y) 5.5% – 35.9%
Revenue CAGR (3Y) 1.3% – -7.8%
Gross profit growth (1Y) 3.9% – 52.4%
Gross profit CAGR (3Y) 1.2% – -2.6%
Operating income growth (1Y) 13.1% – 51.7%
Operating income CAGR (3Y) -3.8% – 22.8%
Net income growth (1Y) 23.6% – 52.7%
Net income CAGR (3Y) -9.9% – 18.5%
EPS growth (1Y) 24.8% – 55.7%
EPS CAGR (3Y) -8.0% – 26.2%
Operating cash flow growth (1Y) 8.6% – 83.0%
Operating cash flow CAGR (3Y) -5.3% – -152.3%
Free cash flow growth (1Y) 14.2% – 82.0%
Free cash flow CAGR (3Y) -5.8% – -26.3%

Profitability

14 metrics
MetricDHRGRFSCDXS
Gross margin 58.6% – 87.0%
EBITDA margin 30.7% – -27.0%
Operating margin 20.4% – -35.6%
Pretax margin 18.8% – -39.5%
Net margin 16.9% – -39.6%
FCF margin 22.4% – -15.7%
Operating cash flow margin 26.8% – -13.4%
Return on equity 8.2% – -80.6%
Return on assets 4.7% – -24.6%
Return on invested capital 5.8% – -35.1%
Return on capital employed 6.2% – -27.3%
Asset turnover 0.3x – 0.6x
Cash conversion (OCF / net income) 1.6x – 0.3x
Stock comp / revenue 1.3% – 9.9%

Financial Health

11 metrics
MetricDHRGRFSCDXS
Debt / assets 28.4% 48.9% 34.0%
Debt / equity 0.5x 1.3x 1.2x
Net debt / EBITDA 2.6x – 0.7x
Debt / FCF 4.6x – -3.4x
Liabilities / assets 42.5% 61.4% 72.5%
Equity / assets 57.5% 38.6% 27.5%
Interest coverage 14.5x – –
Current ratio 1.6x 2.5x 3.1x
Quick ratio 1.1x 0.8x 2.9x
Cash ratio 0.6x 0.4x 2.3x
Altman Z-score 3.77 – -6.27

Shareholder Returns

7 metrics
MetricDHRGRFSCDXS
Dividend yield 0.6% 1.3% –
Net buyback yield 0.5% – -0.3%
Shareholder yield 1.2% 1.3% -0.3%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusDHRGRFSCDXS
Forward P/E 25.8xFY2026 9.1xFY2026 –
EPS, next fiscal year $9.11FY2026 $0.94FY2026 $-0.37FY2026
EPS growth, next FY +16.8%FY2026 +10.6%FY2026 –
EPS growth, the year after +8.0% +26.6% –
Revenue, next fiscal year $27.01BFY2026 $8.88BFY2026 $77.93MFY2026
Revenue growth, next FY +9.9%FY2026 +0.0%FY2026 +10.7%FY2026
Revenue growth, the year after -1.9% +10.3% +9.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersDHRGRFSCDXS
Held by institutions 81.9% 21.0% 71.0%
Institutions holding 2,120 168 148
Change in shares held, QoQ +1.1% -0.5% -2.4%
Institutions buying 842 75 88
Institutions selling 1,015 65 36
Buyers to sellers 0.83 1.15 2.44

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

DHRGRFSCDXS
DHR 1.00 0.18 0.07
GRFS 0.18 1.00 0.14
CDXS 0.07 0.14 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, DHR, GRFS and CDXS?

Danaher (DHR) is the largest by market capitalisation: Danaher (DHR) $164.30B, Grifols (GRFS) $5.82B, Codexis (CDXS) $97.44M.

Which stock is cheaper, DHR, GRFS and CDXS?

Grifols (GRFS) trades on the lowest price-to-earnings ratio (Danaher (DHR) 37.9x, Grifols (GRFS) 12.9x, Codexis (CDXS) -3.2x). On next year's consensus earnings, Grifols (GRFS) is cheapest (Danaher (DHR) 25.8x, Grifols (GRFS) 9.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Codexis (CDXS) grew revenue fastest over the trailing twelve months: Danaher (DHR) +5.5%, Codexis (CDXS) +35.9%.

Which company is more profitable?

Danaher (DHR) has the highest net margin (Danaher (DHR) 16.9%, Codexis (CDXS) -39.6%). On return on invested capital, Danaher (DHR) leads (Danaher (DHR) 5.8%, Codexis (CDXS) -35.1%).

Which stock has performed better?

Over the past year Danaher (DHR) returned the most: Danaher (DHR) +9.9%, Grifols (GRFS) -6.7%, Codexis (CDXS) -50.2%. Over five years, Danaher (DHR) compounded fastest (Danaher (DHR) -4.3%/yr, Grifols (GRFS) -6.8%/yr, Codexis (CDXS) -51.5%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Danaher (DHR) has been the steadiest (Danaher (DHR) 30.8%, Grifols (GRFS) 32.6%, Codexis (CDXS) 87.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, DHR, GRFS and CDXS?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Danaher (DHR) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.